Hoersholm; 14 November 2013 - Medical Prognosis Institute A/S (MPI)
presents data on its multiple biomarker "DRP" that can predict which indication will be approved by the FDA on the Cambridge Healthtech Institute's Fifth Annual ADAPT Congress (Accelerating Development and Advancing Personalized Therapy) in Boston November 4-6 2013.
MPI's lead product DRP (Drug Response Predictor) is a multiple biomarker developed to predict which cancer patients are high likely responders to a given anticancer product. The DRP has been tested in 24 trials where 20 trials were positive. The DRP has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center.
The DRP method can also be used to design the Clinical Development Plan i.e. to select which indications are relevant for a given anticancer drug. Further to and in addition to this, individual patient's gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients who have a high likelihood of response to the drug. The DRP method can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US in 2013.
Data presented at the ADAPT Congress
The data presented at the Congress ranks 65 cancer drugs approved by the FDA. In 21% the approved indication was correctly predicted and in 57% the approved indication was among the top 5 predictions. 73% of the predictions were better than random. For further detailed information please refer to the attached poster which is also placed on the company website.
"This analysis has been performed to demonstrate the statistical accuracy by which MPI's biomarker called DRP can predict which indications will be approved by the FDA - I believe this can be a strong tool for anticancer drug developers" said CSO and founder Steen Knudsen.
"Through the last three decades doctors and drug developers have been forced to use treatments best described as "one size fits all" in spite of the known fact that every cancer is unique. MPI's Drug Response Prediction method takes this fact into consideration. The method is able to analyze huge amounts of complex data from patient's individual biopsies to predict drug response and has therefore the potential of being a long wanted key to Personalized Therapy" CEO Peter Buhl Jensen comments.
For further information please contact
Peter Buhl Jensen, CEO
Cell Phone: +45 21 60 89 22
Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark
MPI is an IT- Medico company with a proprietary method to predict patients sensitivity towards a given anticancer drug by its Drug Response Prediction a gene-tests on tumours. MPI's customers are Pharma and biotech engaged in developing anticancer drugs. MPI's technology has derived from data from more than 3.000 patient's tumours and are validated in 24 clinical studies. The test is broadly applicable in all cancer types and for almost all anticancer therapies. The test is believed to be of high value especially for the very large group of cancer patients for whom there are no other bio-markers available.